Teva Pharmaceutical Industries LimitedTEVANYSE
LOADING
|||
Gross Profit Growth Under Pressure
Trending lower, above historical average, modest growth trend.
Left:
||||
Year-over-year gross profit growth rate
Latest
9.61%
↑ 7668% above average
Average (39q)
0.12%
Historical baseline
Range
High:30.52%
Low:-26.70%
CAGR
+3.3%
Modest growth trend
| Period | Value |
|---|---|
| Q3 2025 | 9.61% |
| Q2 2025 | 11.99% |
| Q1 2025 | -11.46% |
| Q4 2024 | -1.30% |
| Q3 2024 | 6.13% |
| Q2 2024 | 14.29% |
| Q1 2024 | -26.70% |
| Q4 2023 | 30.52% |
| Q3 2023 | 3.06% |
| Q2 2023 | 13.53% |
| Q1 2023 | -10.62% |
| Q4 2022 | 6.05% |
| Q3 2022 | -6.97% |
| Q2 2022 | 3.10% |
| Q1 2022 | -15.12% |
| Q4 2021 | 14.27% |
| Q3 2021 | -4.22% |
| Q2 2021 | -0.27% |
| Q1 2021 | -8.30% |
| Q4 2020 | 10.58% |
| Q3 2020 | 5.05% |
| Q2 2020 | -14.54% |
| Q1 2020 | 5.42% |
| Q4 2019 | 7.00% |
| Q3 2019 | -3.43% |
| Q2 2019 | 2.10% |
| Q1 2019 | -5.89% |
| Q4 2018 | -2.47% |
| Q3 2018 | -1.94% |
| Q2 2018 | -12.22% |
| Q1 2018 | -7.63% |
| Q4 2017 | -3.82% |
| Q3 2017 | -6.31% |
| Q2 2017 | 0.07% |
| Q1 2017 | -16.84% |
| Q4 2016 | 21.03% |
| Q3 2016 | -2.64% |
| Q2 2016 | 3.08% |
| Q1 2016 | -1.97% |
| Q4 2015 | 2.74% |